Article

Effects of short term administration of recombinant human growth hormone to elderly people.

Aging Study Unit, Veterans Administration Medical Center, Palo Alto, California 94034.
Journal of Clinical Endocrinology &amp Metabolism (Impact Factor: 6.31). 03/1990; 70(2):519-27. DOI: 10.1210/jcem-70-2-519
Source: PubMed

ABSTRACT We evaluated the effects of recombinant human GH (rhGH) in 16 men and women more than 60 yr of age. After 10 days of dietary equilibration and control collections, subjects were randomly assigned to receive 0.03, 0.06, or 0.12 mg/kg rhGH by daily injection for 7 days. A brisk rise in circulating somatomedin-C (insulin-like growth factor-I) occurred in all subjects, and this rise was dose dependent. rhGH produced striking changes in nitrogen retention, sodium excretion, and the parathyroid-vitamin D axis. Twenty-four-hour urinary nitrogen excretion decreased from 8.00 +/- 0.33 to 5.01 +/- 0.33 g (P less than 0.001), and sodium excretion decreased from 45.9 +/- 2.96 to 21.2 +/- 3.48 mmol/day (P less than 0.001). Serum calcium concentrations did not change, but serum inorganic phosphorus levels of 1.08 +/- 0.04 mmol/L at baseline increased significantly after rhGH treatment to 1.33 +/- 0.04 mmol/L (P less than 0.001). Increases were also observed in circulating PTH (53.2 +/- 6 vs. 39.5 +/- 4.2 ng/L; P less than 0.01) and calcitriol (82.8 vs. 65.8 pmol/L; P less than 0.05). A rise in serum osteocalcin (10.3 +/- .86 vs. 8.0 +/- 0.5 micrograms/L; P less than 0.05) was accompanied by increased urinary excretion of hydroxyproline (628 +/- 63 vs. 406 +/- 44 mumol/day; P less than 0.01). Despite the reduction in sodium excretion, marked increases were observed in urinary calcium (6.04 +/- 0.97 vs. 3.27 +/- 0.40 mmol/day; P less than 0.01). rhGH significantly impaired oral glucose tolerance and reduced insulin sensitivity, but was otherwise well tolerated and produced no systematic changes in weight or blood pressure. The results of this study indicate that rhGH requires further study as a potential agent for attenuating or reversing the loss of muscle and bone in elderly people.

0 Bookmarks
 · 
45 Views
  • Journal of Anti-Aging Medicine 01/1998; 1(1):9-25.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Resumen El impacto físico, social, económico y psicológico de las fracturas en la mujer; ante el deterioro progresivo de su masa ósea, han sido motivo de enorme interés para médicos e investigadores básicos y clínicos. Al respecto, resulta evidente que las expectativas de vida de la población se han incrementado; debido a la mínima aplicación de la prevención de osteoporosis, particularmen-te en mujeres que no recibieron el apoyo oportuno durante el climaterio, han propiciado un notable incremento en la casuística de mujeres que sufren de osteoporosis en la época contemporánea. El varón también vive más y por ende, es proclive a desarrollar patologías crónicas; entre las cuales, la osteoporosis tiende a hacerse cada vez más frecuente. Sin embargo, existe una notable diferen-cia entre ambos sexos ya que en el hombre, la deficiencia funcional de las células de Leydig, declina gradualmente en forma paulatina y no de manera tan abrupta como sucede a nivel del aparato folicular en los ovarios. Resulta complicado establecer una estrategia diagnóstica accesible y confiable que evalúe por una parte la realidad funcional del aparato testicular; y por la otra no se ha logrado establecer con precisión el diagnóstico de osteoporosis por medio de estudios de densidad mineral ósea y/o de marcadores bioquímicos. En esta revisión se discuten los procedimientos de diagnóstico por imagen, las particularidades endocrino-hormonales y las posibles pautas terapéuticas para esta enfermedad en el varón. Palabras clave: Osteoporosis, masa ósea. Revista de Endocrinología y Nutrición 2000:8(2)Abril-Junio.67-72.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background. Growth hormone (GH) and insulin-like growth factor (IGF-1) are fundamental in skeletal growth during puberty and bone health throughout life. GH increases tissue formation by acting directly and indirectly on target cells; IGF-1 is a critical mediator of bone growth. Clinical studies reporting the use of GH and IGF-1 in osteoporosis and fracture healing are outlined. Methods. A Pubmed search revealed 39 clinical studies reporting the effects of GH and IGF-1 administration on bone metabolism in osteopenic and osteoporotic human subjects and on bone healing in operated patients with normal GH secretion. Eighteen clinical studies considered the effect with GH treatment, fourteen studies reported the clinical effects with IGF-1 administration, and seven related to the GH/IGF-1 effect on bone healing. Results. Both GH and IGF-1 administration significantly increased bone resorption and bone formation in the most studies. GH/IGF-1 administration in patients with hip or tibial fractures resulted in increased bone healing, rapid clinical improvements. Some conflicting results were evidenced. Conclusions. GH and IGF-1 therapy has a significant anabolic effect. GH administration for the treatment of osteoporosis and bone fractures may greatly improve clinical outcome. GH interacts with sex steroids in the anabolic process. GH resistance process is considered.
    International Journal of Endocrinology 01/2014; 2014:235060. · 1.52 Impact Factor